Editorial comment
Cardio-oncology: The future is now!
Cardio-oncologia: o futuro é agora!
Lido
1864
Vezesque se leu este artigo
771
Total PDF
1093
Total HTML
Compartilhar estatísticas
array:24 [ "pii" => "S0870255122003584" "issn" => "08702551" "doi" => "10.1016/j.repc.2022.08.005" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "2019" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "dis" "cita" => "Rev Port Cardiol. 2022;41:985-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S0870255122003687" "issn" => "08702551" "doi" => "10.1016/j.repc.2021.08.017" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "2033" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2022;41:987-97" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Remote versus in-office monitoring for implantable cardioverter defibrillators: Results from a randomized pragmatic controlled study in Portugal" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "987" "paginaFinal" => "997" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Monitoração remota <span class="elsevierStyleItalic">versus</span> seguimento hospitalar presencial em portadores de cardioversor-desfibrilhador: resultados dum estudo randomizado em Portugal" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1878 "Ancho" => 2508 "Tamanyo" => 228393 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Study flowchart (CONSORT 2010).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Mário Oliveira, Milene Fernandes, Hipólito Reis, João Primo, Victor Sanfins, Vânia Silva, Pedro Silva Cunha, Mónica Silva, Paulo J. Nicola" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Mário" "apellidos" => "Oliveira" ] 1 => array:2 [ "nombre" => "Milene" "apellidos" => "Fernandes" ] 2 => array:2 [ "nombre" => "Hipólito" "apellidos" => "Reis" ] 3 => array:2 [ "nombre" => "João" "apellidos" => "Primo" ] 4 => array:2 [ "nombre" => "Victor" "apellidos" => "Sanfins" ] 5 => array:2 [ "nombre" => "Vânia" "apellidos" => "Silva" ] 6 => array:2 [ "nombre" => "Pedro Silva" "apellidos" => "Cunha" ] 7 => array:2 [ "nombre" => "Mónica" "apellidos" => "Silva" ] 8 => array:2 [ "nombre" => "Paulo J." "apellidos" => "Nicola" ] 9 => array:1 [ "colaborador" => "on behalf of the PORTLink Study Investigators" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122003687?idApp=UINPBA00004E" "url" => "/08702551/0000004100000012/v2_202212230532/S0870255122003687/v2_202212230532/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0870255122003572" "issn" => "08702551" "doi" => "10.1016/j.repc.2021.07.014" "estado" => "S300" "fechaPublicacion" => "2022-12-01" "aid" => "2023" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2022;41:979-84" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: An observational study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "979" "paginaFinal" => "984" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Experiência de uma consulta de cardio-oncologia num hospital universitário terciário em Portugal: estudo observacional" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1923 "Ancho" => 1675 "Tamanyo" => 200814 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Primary tumor location and metastatic disease. (a) Primary tumor location. (b) Percentage of primary and metastatic disease.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Manuela Fiuza, Andreia Magalhães, Miguel Nobre Menezes, Paula Costa, Leonor Abreu Ribeiro, Catarina Abreu, Raquel Brás, Joana Vieira, Ana I. Duarte, Pedro Morais, Beatriz Silva, Luís Costa, Fausto J. Pinto" "autores" => array:13 [ 0 => array:2 [ "nombre" => "Manuela" "apellidos" => "Fiuza" ] 1 => array:2 [ "nombre" => "Andreia" "apellidos" => "Magalhães" ] 2 => array:2 [ "nombre" => "Miguel" "apellidos" => "Nobre Menezes" ] 3 => array:2 [ "nombre" => "Paula" "apellidos" => "Costa" ] 4 => array:2 [ "nombre" => "Leonor" "apellidos" => "Abreu Ribeiro" ] 5 => array:2 [ "nombre" => "Catarina" "apellidos" => "Abreu" ] 6 => array:2 [ "nombre" => "Raquel" "apellidos" => "Brás" ] 7 => array:2 [ "nombre" => "Joana" "apellidos" => "Vieira" ] 8 => array:2 [ "nombre" => "Ana I." "apellidos" => "Duarte" ] 9 => array:2 [ "nombre" => "Pedro" "apellidos" => "Morais" ] 10 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Silva" ] 11 => array:2 [ "nombre" => "Luís" "apellidos" => "Costa" ] 12 => array:2 [ "nombre" => "Fausto J." "apellidos" => "Pinto" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122003572?idApp=UINPBA00004E" "url" => "/08702551/0000004100000012/v2_202212230532/S0870255122003572/v2_202212230532/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial comment</span>" "titulo" => "Cardio-oncology: The future is now!" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "985" "paginaFinal" => "986" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Miguel Carvalho, Carla Sousa" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Miguel" "apellidos" => "Carvalho" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 1 => array:4 [ "nombre" => "Carla" "apellidos" => "Sousa" "email" => array:1 [ 0 => "cmcsousa@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Serviço de Cardiologia, Centro Hospitalar e Universitário de São João, Porto, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Cardiovascular R&D Center (UnIC@RISE), Faculdade de Medicina da Universidade do Porto, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Cardio-oncologia: o futuro é agora!" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Every year more than 20 million people worldwide and 60<span class="elsevierStyleHsp" style=""></span>000 in Portugal are diagnosed with cancer.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Outstanding recent advances in cancer treatment have led to an incredible increase in survival, with mortality rates persistently declining. However, not everything is perfect: the increase in survival is associated with higher cardiovascular risk and a greater number of comorbidities, including cardiovascular ones.</p><p id="par0010" class="elsevierStylePara elsevierViewall">In fact, heart disease and cancer are closely linked: they are currently the two most common causes of mortality in the developed world, and they share multiple risk factors (including age, smoking, hypertension, obesity and sedentarism). On the other hand, the presence of heart disease can condition or contra-indicate the choice of cancer treatment. Also, most cancer therapies are associated with adverse cardiovascular effects (including exacerbation of previous disease) and cardiotoxicity. Fortunately, in most cases, when detected and addressed early, cardiotoxicity is reversible. Still, it is one of the principal reasons to withhold cancer therapy and, in some cases, it can lead to irreversible lesions. The multiplicity of cancer therapies currently used can lead to a multiplicity of cardiotoxicity forms, that go beyond left ventricle dysfunction and heart failure (the classic cardio-oncologic presentation), and include arrhythmic or thrombotic events, valvular, and coronary disease.</p><p id="par0015" class="elsevierStylePara elsevierViewall">It is in this particular clinical and epidemiologic setting that cardio-oncology (the new kid on the block) can see its place being sedimented. It is a new cardiology subspeciality that aims to improve patient care before, during and after cancer therapy. In practice, the goals are to screen patients at high risk of cardiotoxicity thus enabling clinical optimization and tailored oncology treatment plans; to detect early and treat cardiovascular complications, minimizing irreversible toxicity and ultimately avoiding the discontinuation of cancer therapy; and to perform adjusted clinical follow-up in cancer survivors.</p><p id="par0020" class="elsevierStylePara elsevierViewall">By fulfilling these purposes, cardio-oncology consultations (COC) can decisively change the prognosis of patients with cancer. However, to provide good cardio-oncology services, patient care needs to be organized in a structured manner. The challenges of creating COC are multiple and demanding. First, there is the need to create a dedicated and specialized multidisciplinary team (cardiologists, oncologists, hematologists, sonographers, and nurses) in a highly demanding healthcare system, with lack of human resources. Secondly, there is the need to keep up to date in a new field, with new therapies that are not familiar to the general cardiologist, which highlights the importance of post-graduate training. Third, there is the need to provide a quick response to colleagues and to patients – oncology treatments ought not to wait and oncologic patients are followed in several different specialties, with multiple hospital visits in a physical and emotionally fragile population. Hence the advantage of walk-in-clinics, with same day electrocardiogram, echocardiogram, nurse and cardiologist evaluation. Last but not least, there is the importance of sharing experience with other centers, aiming for the diffusion of COC. There are several reports<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">2–7</span></a> in the literature about how to set up a COC and how to screen and follow these complex patients; although very useful, they might prove to be difficult to implement in clinical practice.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In the current issue of RPC, Fiúza M. et al.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a> present the experience of one of the first dedicated cardio-oncology programs in Portugal.</p><p id="par0030" class="elsevierStylePara elsevierViewall">At this clinic, over a four-year period, 520 patients were observed, at a total of 1447 patient visits (average of two to three per patient). The most common disease was breast cancer in female patients (also the most common disease in other COC reports). More than 45% of patients underwent treatment with anthracyclines alone or in combination with radiotherapy or HER2-antagonists (therapies with known cardiovascular risks). Twenty percent of patients were referred for pre-chemotherapy screening; nevertheless, most referrals were for suspected cardiac illness (heart failure symptoms, asymptomatic decreased left ventricular ejection fraction, arrythmias and coronary disease). The included population illustrates well the Portuguese and cardio-oncology reality accurately, with 79% of patients presenting with one or more cardiovascular risk factors.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Of note, in this patient cohort, 77% completed cancer treatment and only 16% had to discontinue therapy for cardiac reasons (84% for LV dysfunction); 3% of the total patients had an assumed cardiac-related death (anthracycline-induced heart failure). Remarkably, it was possible to optimize cardiovascular medication in 28% of patients. Also, a significant number of invasive procedures/therapeutics were performed including cardiac resynchronization therapy device implantation, percutaneous coronary intervention, atrial fibrillation catheter ablation and transcatheter aortic valve implantation. These are very interesting data, as previous reports have stated that only half of the patients with cancer and cardiovascular disease are treated with guideline-directed medical therapy.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">To optimize or initiate cardiovascular therapy and, with that intervention, enable the successful conclusion of cancer treatments, is one of the main benefits of COC. As, an example, in an analysis of a breast cancer female population from the COC at our center,<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a> although 10% of patients developed cardiotoxicity, an aggressive therapeutic and surveillance strategy led to treatment interruption in only 22% (temporary in most cases). Of note, most of the patients (94%) presented full cardiac function recovery on follow up.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Still much is unknown in cardio-oncology, mostly derived from the lack of understanding of the fundamental underlying mechanisms of cardiotoxicity, the late diagnosis of myocardial damage (with difficulty to prevent irreversible damage) and absence of specific and effective therapies. Therefore, continuous research to address these gaps in evidence and to further enhance cardiac patient care is of utmost importance. Despite the known difficulties in maintaining clinical activity alongside bedside science, it is important for reference COCs to add this mission to their clinical routine. Fiúza et al. did so by creating a clinical and translational research program.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Clinical experience sharing and continuous education for cardiology and oncology fellows and residents is one of the most effective ways to spread the knowledge in such a vast field as cardio-oncology. Fiúza et al. are an established presence in cardio-oncology sessions at major cardiology meetings, and they have developed a dedicated pre and post-graduate education program.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The authors should be congratulated on their excellent work and for sharing their experience, in order to stimulate the creation/development of similar structures in other centers of the country. This triad of a clinic, research and education program should be regarded as an example of success and one that can be replicated.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Despite its rapid evolution, cardio-oncology still has a long way to go and multiple challenges to overcome. Several questions come to our minds: will there be a role for new early markers of cardiotoxicity? What part will multimodality imaging play in cardio-oncology? Will global longitudinal strain directed therapy have a place in the new European Society of Cardiology recommendations? Will new discoveries lead to better screening and new therapeutic targets? What will translational medicine bring us – cell therapy and mitochondria transplantation? What is the role of cardiac rehabilitation in COC? And what about primary prevention?</p><p id="par0065" class="elsevierStylePara elsevierViewall">The future is exciting as we await the answers. Meanwhile, as cardio-oncologists, let us use Fiuza's example to improve the cardiac care of the oncological patients of today, to prevent them from becoming our cardiac patients of tomorrow.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0070" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020<span class="elsevierStyleItalic">.</span> [homepage on the internet]; 2020. Available from: <a target="_blank" href="https://gco.iarc.fr/today/fact-sheets-cancers">https://gco.iarc.fr/today/fact-sheets-cancers</a> [cited 23.07.22]." ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "I. Costa" 1 => "C. Bittar" 2 => "S. Fonseca" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12872-020-01471-8" "Revista" => array:5 [ "tituloSerie" => "BMC Cardiovasc Disord" "fecha" => "2020" "volumen" => "20" "paginaInicial" => "206" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32345217" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Kappel" 1 => "M. Rushton" 2 => "C. Johnson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3747/co.26.4509" "Revista" => array:6 [ "tituloSerie" => "Curr Oncol" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "e322" "paginaFinal" => "e327" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31285675" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Practical and cost-effective model to build and sustain a cardio-oncology program" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Sadler" 1 => "C. Chaulagain" 2 => "B. Alvarado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s40959-020-00063-x" "Revista" => array:5 [ "tituloSerie" => "Cardio-Oncology" "fecha" => "2020" "volumen" => "6" "paginaInicial" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32690995" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Sulpher" 1 => "S. Mathur" 2 => "N. Graham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2015/671232" "Revista" => array:5 [ "tituloSerie" => "J Oncol" "fecha" => "2015" "volumen" => "2015" "paginaInicial" => "671232" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26300917" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiology consultation in oncology practice: a 5-year survey" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K. Tajiri" 1 => "I. Sekine" 2 => "H. Naito" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jjco/hyaa118" "Revista" => array:6 [ "tituloSerie" => "Jpn J Clin Oncol" "fecha" => "2020" "volumen" => "50" "paginaInicial" => "1419" "paginaFinal" => "1425" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32676637" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Organization and implementation of a cardio-oncology program" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Fiuza" 1 => "L. Ribeiro" 2 => "A. Magalhães" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repc.2016.04.006" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2016" "volumen" => "35" "paginaInicial" => "485" "paginaFinal" => "494" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27503589" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: an observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Fiuza" 1 => "A. Magalhães" 2 => "M.N. Menezes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repc.2021.07.014" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2022" "volumen" => "41" "paginaInicial" => "979" "paginaFinal" => "984" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36153294" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.G. Al-Kindi" 1 => "G.H. Oliveira" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.mayocp.2015.09.009" "Revista" => array:6 [ "tituloSerie" => "Mayo Clin Proc" "fecha" => "2016" "volumen" => "91" "paginaInicial" => "81" "paginaFinal" => "83" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26602599" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiotoxicity in breast cancer patients – risk factors and role of cardioprotective drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Martins de Carvalho" 1 => "R. Pinto" 2 => "T. Proença" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2022" "volumen" => "41 Especial Congresso" "paginaInicial" => "58" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08702551/0000004100000012/v2_202212230532/S0870255122003584/v2_202212230532/en/main.assets" "Apartado" => array:4 [ "identificador" => "93359" "tipo" => "SECCION" "pt" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "pt" ] "PDF" => "https://static.elsevier.es/multimedia/08702551/0000004100000012/v2_202212230532/S0870255122003584/v2_202212230532/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255122003584?idApp=UINPBA00004E" ]
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Novembro | 6 | 5 | 11 |
| 2024 Outubro | 60 | 37 | 97 |
| 2024 Setembro | 50 | 38 | 88 |
| 2024 Agosto | 53 | 44 | 97 |
| 2024 Julho | 49 | 32 | 81 |
| 2024 Junho | 52 | 22 | 74 |
| 2024 Maio | 47 | 25 | 72 |
| 2024 Abril | 47 | 24 | 71 |
| 2024 Maro | 61 | 30 | 91 |
| 2024 Fevereiro | 61 | 28 | 89 |
| 2024 Janeiro | 44 | 29 | 73 |
| 2023 Dezembro | 44 | 29 | 73 |
| 2023 Novembro | 51 | 38 | 89 |
| 2023 Outubro | 34 | 45 | 79 |
| 2023 Setembro | 22 | 26 | 48 |
| 2023 Agosto | 32 | 15 | 47 |
| 2023 Julho | 43 | 50 | 93 |
| 2023 Junho | 40 | 33 | 73 |
| 2023 Maio | 32 | 24 | 56 |
| 2023 Abril | 11 | 6 | 17 |
| 2023 Maro | 26 | 20 | 46 |
| 2023 Fevereiro | 31 | 34 | 65 |
| 2023 Janeiro | 40 | 33 | 73 |
| 2022 Dezembro | 121 | 67 | 188 |
| 2022 Novembro | 36 | 37 | 73 |
Mostrar tudo
